Search | Clinical Trials Finder

Conditions: Contraceptive Usage
Interventions: levonorgestrel butanoate; Biological
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy Participants
Interventions: Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG]); Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Endometriosis
Interventions: norethindrone acetate (NETA), Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 13 Years to 24 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Contraception
Interventions: Ulipristal Acetate, Levonorgestrel; Drug
Lead sponsor: Kimberly Myer; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 532 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 18
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 14 more

Conditions: Dyslipidaemia
Interventions: AZD0780, Itraconazole, Carbamazepine, Midazolam, Ethinyl estradiol/levonorgestrel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Epithelial Ovarian Cancer
Interventions: Mirena® intra-uterine device (IUD); Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 35 Years to 50 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: HIV Infections
Interventions: GSK3640254, Portia; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Participants
Interventions: AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP), AZD9550; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Contraception
Interventions: Gestodene/EE (FC Patch Low, BAY86-5016), Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 346 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 28
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 25 more

Conditions: Menopausal and Other Perimenopausal Disorders
Interventions: Mirena, Estradiol, Placebo Gel; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 52 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
Interventions: Tamoxifen, Placebo (for Tamoxifen); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Contraception
Interventions: CDB-2914, Levonorgestrel; Drug
Lead sponsor: HRA Pharma; Industry
Eligibility: 16 Years and older · Female only
Enrollment: 2,221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 23
States / cities: Los Angeles, California • Santa Monica, California • Boulder, Colorado + 18 more

Conditions: Menorrhagia
Interventions: Levonorgestrel IUS (Mirena, BAY86-5028), Medroxyprogesterone acetate; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 37
States / cities: Tucson, Arizona • Beverly Hills, California • Carmichael, California + 32 more

Conditions: Premenstrual Syndrome
Interventions: Levonorgestrel/Ethinyl Estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 48
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 40 more

Conditions: Contraception
Interventions: Copper IUD, Levonorgestrel IUD; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Logan, Utah • Ogden, Utah • Orem, Utah + 3 more

Conditions: Endometrioid Endometrial Adenocarcinoma
Interventions: Glucagon-like peptide 1 receptor agonist; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Ovarian Carcinoma
Interventions: Laboratory Biomarker Analysis, Levonorgestrel, Placebo; Other · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 30 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 66
States / cities: Duarte, California • Los Angeles, California • Orange, California + 46 more

Conditions: Levonorgestrel, Intrauterine Systems, Prevention, Endometrial Cancer
Interventions: Survey using a questionnaire; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Contraception
Interventions: LNG20, Mirena; Drug
Lead sponsor: Medicines360; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 1,910 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2021
U.S. locations: 25
States / cities: Phoenix, Arizona • Palo Alto, California • San Francisco, California + 22 more

Conditions: Menorrhagia
Interventions: Levonorgestrel 52 mg intrauterine system; Combination Product
Lead sponsor: Medicines360; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 29
States / cities: Scottsdale, Arizona • Sacramento, California • San Diego, California + 25 more

Conditions: Pregnancy, Unplanned, Pregnancy; Accident
Interventions: Ulipristal acetate, levonorgestrel IUS; Drug · Device
Lead sponsor: Planned Parenthood of the St. Louis Region and Southwest Missouri; Other
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 274 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 3
States / cities: Atlanta, Georgia • Indianapolis, Indiana • St Louis, Missouri

Conditions: Healthy Female Participants
Interventions: Zibotentan, EE/LNG; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Contraception
Interventions: Kyleena; Drug
Lead sponsor: Bayer; Industry
Eligibility: Female only
Enrollment: 1,134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 12
States / cities: Lakewood, Colorado • Sarasota, Florida • Wellington, Florida + 9 more

Conditions: Contraceptive Usage
Interventions: Levonorgestrel IUD; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

A Phase I Study to Evaluate the PK and PD of a Single Injection of Levonorgestrel Butanoate for Female Contraception

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

IUD and Norethindrone Acetate for Treatment of Endometriosis

Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation

Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

US Cycle Control and Blood Pressure Study

Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception

Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)

Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS

RAPID EC - Rct Assessing Pregnancy With Intrauterine Devices for EC

A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer

A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

Levonorgestrel Intrauterine System For Emergency Contraception

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method

'Levonorgestrel IUD Insertion After D&E Procedure